New development program for mild dry eye based on IntelliGel platform 

We are launching the new program to develop treatments based on IntelliGel to help patients suffering from mild dry eye. IntelliGel, the carrier used in RP101 estrogen therapy, alone showed significant activity in safely relieving both signs and symptoms of dry eye disease. We now seek to develop IntelliGel as a treatment for mild dry eye disease targeting both men and women of all ages needing temporary relief.

After Redwood Pharma conducted a market survey of mild sufferers in the US and Europe, the results of the survey confirmed that there is a need for new therapies that can address mild or transient symptoms. This will also improve patient convenience by reducing the number of administrations needed. 

The commercial opportunity is very substantial with over 15 million diagnosed patients of mild dry eye in both the US and Europe. This new program will expand the company’s portfolio, offering therapeutic relief to a much broader market.


Topical eye treatment for daily use by post-menopausal women

Our first product candidate is based on a naturally occurring, endogenous molecule found in the body. In prior clinical trials, the molecule, when used as an active pharmaceutical ingredient, was found to be associated with the mechanism of tear film production. Redwood proposes to restore the natural levels of this molecule by administration by way of an eye drop. This treatment is thought to promote tear film production which is needed to properly lubricate the front of the eye. The Redwood team and other scientists have already confirmed the significant correlation between this active substance and its subsequent reduction of symptoms of Dry Eye Disease (DED) in human clinical trials.

Dry Eye Disease

Sufferers of dry eye experience dryness, pain, stinging, burning, redness, itchiness, blurred vision, mucus discharge and general discomfort in the front of the eye – impairing people in basic daily functions such as reading, operating machinery and driving an automobile.  In its severest form it is even debilitating.  If not treated, some cases of dry eye can lead to damage of the ocular surface and even potential blindness.

DED is caused by many factors including inflammation, dysfunction of glands & cells in and around the eye.  Ageing, contact lens use and dry environments can increase the risk of obtaining DED.  Patients are forced to used standard over-the-counter eye drops or a combination of other drugs and surgery to try to alleviate their symptoms with the hope of finding any type of effect.  There is currently no product on the market today that addresses the root cause of DED.